Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.

Kimura T, Kubo M, Takahashi K, Wamata R, Iwamoto Y, Iwamoto H, Katakura Y, Sanada J, Fushimi Y, Shimoda M, Tatsumi F, Nakanishi S, Mune T, Kaku K, Kaneto H

Journal of diabetes research4 Jan 2024Cited by 3 (Europe PMC)

PMID38223524PMCIDPMC10783983DOI10.1155/2024/5880589PepBankPUB-38223524

Download PDF PubMedAsk about this study

Jump to 8 results

Summary

Recently, the development of once-weekly incretin-based injections dulaglutide and semaglutide has drawn a great deal of attention. This study is aimed at comparing the efficacy of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide and semaglutide on glycemic control and several metabolic parameters in patients with type 2 diabetes mellitus. We compared various clinical parameters between before and after switching from dulaglutide to semaglutide in "study 1" (pre-post comparison) and set the control group using propensity score matching method in "study 2." In "study 1," six months after the switching, HbA1c was significantly reduced from 8.2% to 7.6% and body mass index was also decreased from 30.4 kg/m² to 30.0 kg/m². Such effects were more pronounced in subjects whose glycemic control was poor. In "study 2," after 1 : 1 propensity score matching, glycemic control and body weight management were improved in the switching group compared with the dulaglutide continuation group. In this study including obese subjects with poor glycemic control, switching dulaglutide to semaglutide showed more beneficial effects on both glycemic and weight control irrespective of age, body weight, and diabetes duration. Therefore, we should bear in mind that it would be better to start using a relatively new once-weekly GLP-1RA semaglutide in clinical practice, especially in obese subjects with poor glycemic control with other GLP-1RAs.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, HbA1c fell from 8.2% to 7.6% six months after switching from dulaglutide to semaglutide.
In plain wordsIn adults with type 2 diabetes, HbA1c fell after switching from dulaglutide to semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change after switching from dulaglutide, study 1
Study
n: not reported in source
Comparator
Before switching (dulaglutide)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
HbA1c
8.2%
before switching
HbA1c
7.6%
6 months after switching
Source sentences
Summary
In "study 1," six months after the switching, HbA1c was significantly reduced from 8.2% to 7.6% and body mass index was also decreased from 30.4 kg/m² to 30.0 kg/m².
2 context sentences(design, population, supporting numbers)
Summary · context
This study is aimed at comparing the efficacy of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide and semaglutide on glycemic control and several metabolic parameters in patients with type 2 diabetes mellitus.
Summary · context
We compared various clinical parameters between before and after switching from dulaglutide to semaglutide in "study 1" (pre-post comparison) and set the control group using propensity score matching method in "study 2."
Show in the study text Report a problemFND-3822352401
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, body mass index fell from 30.4 to 30.0 kg/m2 six months after switching from dulaglutide to semaglutide.
In plain wordsIn adults with type 2 diabetes, body mass index fell slightly after switching from dulaglutide to semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody mass index change after switching from dulaglutide, study 1
Study
n: not reported in source
Comparator
Before switching (dulaglutide)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
BMI
30.4 kg/m<sup>2</sup>
before switching
BMI
30 kg/m<sup>2</sup>
6 months after switching
Source sentences
Summary
In "study 1," six months after the switching, HbA1c was significantly reduced from 8.2% to 7.6% and body mass index was also decreased from 30.4 kg/m² to 30.0 kg/m².
2 context sentences(design, population, supporting numbers)
Summary · context
This study is aimed at comparing the efficacy of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide and semaglutide on glycemic control and several metabolic parameters in patients with type 2 diabetes mellitus.
Summary · context
We compared various clinical parameters between before and after switching from dulaglutide to semaglutide in "study 1" (pre-post comparison) and set the control group using propensity score matching method in "study 2."
Show in the study text Report a problemFND-3822352402
03HumanObservational studyEfficacy outcome
The reductions in HbA1c and BMI after switching to semaglutide were larger in subjects with poor glycaemic control.
In plain wordsSwitching to semaglutide had larger effects in people whose blood sugar control was poor.
Peptide
Semaglutide
Outcome
Not applicableEffect size by baseline glycaemic control, study 1
Study
n: not reported in source
Comparator
Before switching (dulaglutide)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Such effects were more pronounced in subjects whose glycemic control was poor.
2 context sentences(design, population, supporting numbers)
Summary · context
This study is aimed at comparing the efficacy of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide and semaglutide on glycemic control and several metabolic parameters in patients with type 2 diabetes mellitus.
Summary · context
We compared various clinical parameters between before and after switching from dulaglutide to semaglutide in "study 1" (pre-post comparison) and set the control group using propensity score matching method in "study 2."
Show in the study text Report a problemFND-3822352403
04HumanObservational studyEfficacy outcome
After propensity score matching, glycaemic control improved in the group switched to semaglutide compared with the dulaglutide continuation group.
In plain wordsBlood sugar control improved more in people who switched to semaglutide than in people who stayed on dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseGlycaemic control versus dulaglutide continuation, study 2
Study
n: not reported in source
Comparator
Dulaglutide continuation
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
In "study 2," after 1 : 1 propensity score matching, glycemic control and body weight management were improved in the switching group compared with the dulaglutide continuation group.
2 context sentences(design, population, supporting numbers)
Summary · context
This study is aimed at comparing the efficacy of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide and semaglutide on glycemic control and several metabolic parameters in patients with type 2 diabetes mellitus.
Summary · context
We compared various clinical parameters between before and after switching from dulaglutide to semaglutide in "study 1" (pre-post comparison) and set the control group using propensity score matching method in "study 2."
Show in the study text Report a problemFND-3822352404
05HumanObservational studyEfficacy outcome
After propensity score matching, body weight management improved in the group switched to semaglutide compared with the dulaglutide continuation group.
In plain wordsWeight control improved more in people who switched to semaglutide than in people who stayed on dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight management versus dulaglutide continuation, study 2
Study
n: not reported in source
Comparator
Dulaglutide continuation
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
In "study 2," after 1 : 1 propensity score matching, glycemic control and body weight management were improved in the switching group compared with the dulaglutide continuation group.
2 context sentences(design, population, supporting numbers)
Summary · context
This study is aimed at comparing the efficacy of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide and semaglutide on glycemic control and several metabolic parameters in patients with type 2 diabetes mellitus.
Summary · context
We compared various clinical parameters between before and after switching from dulaglutide to semaglutide in "study 1" (pre-post comparison) and set the control group using propensity score matching method in "study 2."
Show in the study text Report a problemFND-3822352405
06HumanObservational studyEfficacy outcome
In obese subjects with poor glycaemic control, the benefit of switching from dulaglutide to semaglutide on glycaemic and weight control did not depend on age, body weight or diabetes duration.
In plain wordsIn obese people with poor blood sugar control, the benefit of switching to semaglutide did not depend on age, weight or diabetes duration.
Peptide
Semaglutide
Outcome
Not applicableGlycaemic and weight control across age, body weight and diabetes duration
Study
n: not reported in source
Comparator
Dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
In this study including obese subjects with poor glycemic control, switching dulaglutide to semaglutide showed more beneficial effects on both glycemic and weight control irrespective of age, body weight, and diabetes duration.
2 context sentences(design, population, supporting numbers)
Summary · context
This study is aimed at comparing the efficacy of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide and semaglutide on glycemic control and several metabolic parameters in patients with type 2 diabetes mellitus.
Summary · context
We compared various clinical parameters between before and after switching from dulaglutide to semaglutide in "study 1" (pre-post comparison) and set the control group using propensity score matching method in "study 2."
Show in the study text Report a problemFND-3822352406
07HumanObservational studyEfficacy outcome
In patients with T2D, continued dulaglutide was linked to poorer glycemic control than switching to semaglutide after propensity matching.
In plain wordsIn patients with diabetes, continued dulaglutide was linked to poorer blood sugar control than switching to semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedGlycemic control
Study
n: not reported in source
Comparator
Switching from dulaglutide to semaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
In "study 2," after 1 : 1 propensity score matching, glycemic control and body weight management were improved in the switching group compared with the dulaglutide continuation group.
2 context sentences(design, population, supporting numbers)
Summary · context
This study is aimed at comparing the efficacy of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide and semaglutide on glycemic control and several metabolic parameters in patients with type 2 diabetes mellitus.
Summary · context
We compared various clinical parameters between before and after switching from dulaglutide to semaglutide in "study 1" (pre-post comparison) and set the control group using propensity score matching method in "study 2."
Show in the study text Report a problemFND-3822352407
08HumanObservational studyEfficacy outcome
In patients with T2D, continued dulaglutide was linked to poorer weight management than switching to semaglutide after propensity matching.
In plain wordsIn patients with diabetes, continued dulaglutide was linked to poorer weight control than switching to semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedBody weight management
Study
n: not reported in source
Comparator
Switching from dulaglutide to semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
In "study 2," after 1 : 1 propensity score matching, glycemic control and body weight management were improved in the switching group compared with the dulaglutide continuation group.
2 context sentences(design, population, supporting numbers)
Summary · context
This study is aimed at comparing the efficacy of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide and semaglutide on glycemic control and several metabolic parameters in patients with type 2 diabetes mellitus.
Summary · context
We compared various clinical parameters between before and after switching from dulaglutide to semaglutide in "study 1" (pre-post comparison) and set the control group using propensity score matching method in "study 2."
Show in the study text Report a problemFND-3822352408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms